Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03984305 · ClinicalTrials.gov registry record · NA
Utilization of Target Ranges to Treat Parkinson's Disease With the PKG
A NA study, sponsored by Global Kinetics Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT03984305: Clinical Trial NA study, sponsored by Global Kinetics Corporation.
NCT03984305 is a NA study that was terminated before completion, run by Global Kinetics Corporation. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03984305, a NA study, was terminated before completion, sponsored by Global Kinetics Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate whether people whose PD symptoms are uncontrolled who are managed with the aid of objective measurement and use of target ranges have improved PD symptoms and outcomes as compared to individuals treated using only standard of care (medical history, neurological examination).
Primary Outcome
The change in total MDS-UPDRS score at 4 months from baseline defined as sections I, II, III and IV in Patients with Parkinson's. The endpoint will be compared between those who are treated with standard of care and access to the PKG (PKG+ Group) and those who are treated per standard of care alone (PKG- Group). The MDS-UPDRS evaluates motor and non-motor symptoms in persons with Parkinson's and consists of 4 parts with various questions and evaluations. Parts I and II (non-motor) each contain 1
Interventions
- DEVICE Personal KinetiGraph® (PKG®) Watch
- DEVICE Personal KinetiGraph® (PKG®) Report
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2020-10-16 |
| Phase | NA |
Why NCT03984305 stopped before completion
NCT03984305 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Personal KinetiGraph® (PKG®) Watch is the first listed.
NCT03984305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03984305 about?
NCT03984305 is a clinical study titled "Utilization of Target Ranges to Treat Parkinson's Disease With the PKG". The main objective of this study is to evaluate whether people whose PD symptoms are uncontrolled who are managed with the aid of objective measurement and use of target ranges have improved PD symptoms and outcomes as compared to individuals treated using only standard of care (medical history, neu...
What is the current status of trial NCT03984305?
This trial is currently terminated. It is a NA study. The enrollment target is 41 participants. The study started on 2019-10-15. Estimated completion is 2020-10-16.
What interventions are being tested in trial NCT03984305?
The interventions under investigation include: Personal KinetiGraph® (PKG®) Watch (DEVICE), Personal KinetiGraph® (PKG®) Report (DEVICE).
Who is sponsoring clinical trial NCT03984305?
This trial is sponsored by Global Kinetics Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03984305's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI